Floatz logo

Durvalumab

Metastatic Urothelial Carcinoma

Alliance for Clinical Trials in Oncologymonoclonal_antibodyPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Metastatic Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Vasgene Therapeutics, Inc
Phase 2/3BB
Irinotecan
Pfizer
Phase 3BB
(+)-VINCRISTINE
Pfizer
Phase 3BB
Olaparib
Rahul Aggarwal
Phase 2BB
Recombinant Ephb4-Hsa Fusion Protein
Vasgene Therapeutics, Inc
Phase 2/3CCC

View all 21 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →